Actovegin 40mg/ml, 5 ampoules
Solution for injections 200 mg ampoule 5 ml, No. 5
Deproteinized hemoderivative of calf blood 40 mg/ml.
Actovegin contains only physiologically active substances with a molecular weight of !$#lt#$!5000 Da. At the molecular level, the drug accelerates the uptake of oxygen (increases resistance to hypoxia) and glucose, thereby contributing to an increase in energy metabolism. The overall effect of these processes is enhancement of the energy state of the cell, especially under conditions of hypoxia and ischemia.
Influence of Actovegin on the absorption and utilization of oxygen, as well as insulin-like activity with stimulation of glucose transport and oxidation, are important in the treatment of diabetic polyneuropathy. In patients with diabetes mellitus and diabetic polyneuropathy (stabbing pain, burning sensation, paresthesia, numbness in the lower extremities), the severity of sensory impairment objectively decreases, mental health improves.
With the help of pharmacokinetic methods, it is impossible to study the pharmacokinetic properties (absorption, distribution and elimination of the active ingredients of the drug) of Actovegin, as the drug contains only physiologically active components that are usually present in the body.
Metabolic and circulatory disorders of the CNS – ischemic strokes, residual effects of hemorrhagic strokes, traumatic brain injuries, encephalopathy of various origin.
Diabetic peripheral polyneuropathy.
Disorders of peripheral arterial or venous circulation, angiopathies, including those of diabetic origin; first to third degree burns (chemical, thermal, solar, radiation burns). Wound healing (ulcers of various etiologies, trophic disorders, bedsores, impaired wound healing); radiation damage to the skin, mucous membranes, radiation neuropathies.
the drug is administered used intravenously (bolus, drop infusion), intra-arterially 5–20 ml per day. Intramuscularly, the drug should be administered slowly, no more than 5 ml per day.
For intravenous administration, the drug is diluted in 0.9% solution of sodium chloride or 5% solution of glucose. Permissible final concentration of Actovegin may be up to 2000 mg of dry matter per 250 ml of solution.
Usual recommended regimen: considering the clinical symptoms, first 5–10 ml intravenously. or intra-arterially, further - 5 ml intravenously or slowly intramuscularly daily or several times a week.
Doses depending on the indications.
In severe conditions, Actovegin is intravenously administered by drop infusion 20–50 ml per day for several days until a pronounced clinical effect is achieved.
In conditions of moderate severity or exacerbation of chronic diseases, the drug is administered intravenously or intramuscularly at a dose of 5–20 ml per day for 14–17 days.
When carrying out a planned course of treatment, 2–5 ml / day is administered intravenously or intramuscularly for 4–6 weeks. The frequency of administration is 1 to 3 times depending on the severity of the disease.
In diabetic polyneuropathy, treatment begins with intravenous administration of the drug at a dose of 2 g per day for 3 weeks, followed by switching to 2-3 tablets 3 times a day for at least 4-5 months.
Hypersensitivity to the drug.
The drug is usually well tolerated. Rarely, anaphylactoid (allergic) reactions, anaphylactic shock can occur, which can manifest as: immune disorders – skin hyperemia, rash, itching, urticaria, increased sweating, chills, swelling of the skin and/or mucous membranes, angioedema, flushing, fever;
- digestive tract disorders – dyspeptic phenomena, including pain in the upper abdomen, nausea, vomiting, diarrhea;
- cardiovascular system disorders – heart pains, increased heart rate (tachycardia), shortness of breath, acrocyanosis, pallor of the skin, arterial hypotension or hypertension;
- respiratory disorders – rapid breathing, chest tightness, difficulty in swallowing and/or breathing, sore throat, asthma attacks;
- nervous system disorders – headache, general weakness, dizziness, loss of consciousness, agitation, trembling (tremor), paresthesia;
- musculoskeletal system disorders – muscle and/or joint pain, back pain;
- common disorders – reactions at the injection site.
- In such cases, treatment with Actovegin should be stopped and symptomatic therapy should be applied.
It is desirable to inject no more than 5 ml of the drug solution intramuscularly, since it is hypertonic.
In connection with the possibility of anaphylactic reactions, it is recommended to carry out a test injection (2 ml of the drug solution is injected intramuscularly with an assessment of the local and general reaction).
The injection solution is compatible with an isotonic solution of sodium chloride and an isotonic solution of glucose.
Actovegin is not recommended to be mixed with other solutions, except for the above.
The injection solution has a yellowish tint, the intensity of which depends on the batch number and the starting material, but the color of the solution does not affect the effectiveness and its sensitivity.
Pregnancy and breastfeeding.
Actovegin should be used only in cases where potential benefit to the mother outweighs any potential risk to the fetus or the child.
The drug is not used in pediatric practice.
The ability to influence the reaction rate when driving and working with mechanisms has not been studied, but possible manifestations of side effects on the part of the nervous system should be taken into account (see adverse events).
Interaction with other medicinal products
The injection solution is compatible with the isotonic solution of sodium chloride and isotonic glucose solution. Actovegin is not recommended to be mixed with other solutions, except for the above. There are no data on the interaction of Actovegin with other drugs.
No known cases of overdose.
Store in the dark place at a temperature not exceeding 25 °C.